The Latest “Buzz on the Street” Show: Featuring MediPharm Labs (OTCQB: MLCPF) (TSX-V: LABS) News’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “MediPharm Labs Signs First International Private Label Sale Agreement With AusCann for Cannabis Oil Export to Australia”

MediPharm Labs Corp. (OTCQB: MLCPF) (TSX-V: LABS) is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc., has entered into its first definitive international sales agreement, dated February 20, 2019, with AusCann Group Holdings Ltd. to supply private label purified, pharmaceutical grade cannabis oil concentrates, or resin, from MediPharm Labs’ own inventory of oil for export to Australia.

Founded in 2015, MediPharm Labs has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the ACMPR without first receiving a cannabis cultivation licence.

The cannabis industry saw strong investor support throughout 2018, which had also carried over into 2019. A slew of new cannabis companies listed their stocks on various exchanges such as the Canadian Securities Exchange, the New York Stock Exchange, and the Nasdaq Stock Exchange. While many of those to have listed are still small-cap companies, the booming industry has allowed some to capitalize on the opportunity and become multi-billion dollar corporations. Large investments are also pouring into the market from other sectors such as the beverage and tobacco industry, further fueling development. Even though the industry is witnessing a robust momentum, the concern over federal regulatory laws remains. Nonetheless, based on current milestones, such as Canada legalizing cannabis entirely and more U.S. states adopting positive legislative stances on the plant, the industry has the potential to broaden into an explosive market. According to data compiled by MarketsandMarkets research, the global cannabis market size is expected to grow from USD 10.3 Billion in 2018 to USD 39.4 Billion by 2023. Additionally, the market is projected to increase at a CAGR of 30.7% throughout the forecast period. 

Due to the illegal nature of the cannabis industry, the medical segment currently accounts for the majority of the overall market value. Many countries have legalized cannabis for medical applications to treat conditions such as arthritis, chronic pain, and cancer. However, the recreational segment is witnessing substantial acceleration, primarily driven by concentrates. Regardless of the application though, the THC-dominant sector is propelling the overall industry growth. THC remains heavily regulated as opposed to its counterpart, CBD, because of its psychoactive effects. Yet, THC is also increasingly becoming adopted for both recreational and medical purposes due to its potent effects, causing it to hold the largest market share as well as register the highest CAGR among cannabis segments. Via Forbes, Scott Greiper, the President of Viridian Capital Advisors, said that the pace of legalization is accelerating around the world, not just in the U.S., for both medical and recreational marijuana. Greiper notes that the biggest drivers for creating a large consumer market are: the lifting of the stigma of marijuana; globalization; more advanced technology for agriculture, genetics, biotechnology, and the extraction business coming into a mom-and-pop industry. “This is a very dynamic marketplace for investors and acquirers,” said Greiper. “This is driving companies to become more efficient and more profitable operators.”

For more information, please visit: MediPharm Labs Corp.

For more corporate news on MediPharm Labs Corp., check out the Buzz on the Street

About Buzz on the Street: One of’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure


  1. Kase Hannah 3 months ago

    cannabis oil has provided my Grandpa with immense relief as he has arthritis on his elbows and knees. Usually simple tasks such as walking and eating are a bit difficult, but I notice he feels much better after taking some cannabis oil. He also has a cream but prefers utilizing the oil.

    • Gurjant Singh 3 months ago

      is there a cannabis oil nebulizer? I fear normal smoke is too hot for some my grandpa to take.

      • John Castillo 3 months ago

        currently, there is not but I’m sure the technological advancements in cannabis product/use will blossom as legalization ensues.

Leave a Comment

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For medipharm labs corporation, financial and corporate news dissemination, expects to be compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: